Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes

• Published in: Leukemia research Vol. 38; no. 5; pp. 557 - 563
• Main Authors: Delforge, Michel, Selleslag, Dominik, Beguin, Yves, Triffet, Agnès, Mineur, Philippe, Theunissen, Koen, Graux, Carlos, Trullemans, Fabienne, Boulet, Dominique, Van Eygen, Koen, Noens, Lucien, Van Steenweghen, Steven, Lemmens, Jan, Pierre, Pascal, D’hondt, Randal, Ferrant, Augustin, Deeren, Dries, Van De Velde, Ann, Wynendaele, Wim, André, Marc, De Bock, Robrecht, Efira, André, Breems, Dimitri, Deweweire, Anne, Geldhof, Kurt, Pluymers, Wim, Harrington, Amanda, MacDonald, Karen, Abraham, Ivo, Ravoet, Christophe
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.05.2014
• Subjects: Aged; Blood Transfusion; Cardiac death; Chelation therapy; Female; Hematology, Oncology and Palliative Medicine; Humans; Iron Chelating Agents - therapeutic use; Iron overload; Male; Middle Aged; Myelodysplastic syndromes; Myelodysplastic Syndromes - drug therapy; Myelodysplastic Syndromes - mortality; Retrospective Studies; Risk; Time Factors; Transfusion; Transfusion dependency; Iron overload; Transfusion; Transfusion dependency; Cardiac death; Chelation therapy; Myelodysplastic syndromes

Abstract Background Most patients with myelodysplastic syndromes (MDS) require transfusions at the risk of iron overload and associated organ damage, and death. Emerging evidence indicates that iron chelation therapy (ICT) could reduce mortality and improve survival in transfusion-dependent MDS pati...